Solicitation of Nomination for Appointment to the Advisory Committee on Blood Safety and Availability, 22865-22866 [05-8773]
Download as PDF
<![CDATA[
Federal Register / Vol. 70, No. 84 / Tuesday, May 3, 2005 / Notices
FEDERAL RESERVE SYSTEM
Change in Bank Control Notices;
Acquisition of Shares of Bank or Bank
Holding Companies
The notificants listed below have
applied under the Change in Bank
Control Act (12 U.S.C. 1817(j)) and
§ 225.41 of the Board’s Regulation Y (12
CFR 225.41) to acquire a bank or bank
holding company. The factors that are
considered in acting on the notices are
set forth in paragraph 7 of the Act (12
U.S.C. 1817(j)(7)).
The notices are available for
immediate inspection at the Federal
Reserve Bank indicated. The notices
also will be available for inspection at
the office of the Board of Governors.
Interested persons may express their
views in writing to the Reserve Bank
indicated for that notice or to the offices
of the Board of Governors. Comments
must be received not later than May 17,
2005.
A. Federal Reserve Bank of Boston
(Richard Walker, Community Affairs
Officer) 600 Atlantic Avenue, Boston,
Massachusetts 02106-2204:
1. John D. Doherty together with
Joseph R. Doherty Family Limited
Partnership, L.P., to acquire voting
shares of Central Bancorp, Inc.,
Somerville, Massachusetts, and thereby
indirectly acquire Central Cooperative
Bank, Somerville, Massachusetts.
Board of Governors of the Federal Reserve
System, April 27, 2005.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. 05–8741 Filed 5–2–05; 8:45 am]
BILLING CODE 6210–01–S
available for inspection at the offices of
the Board of Governors. Interested
persons may express their views in
writing on the standards enumerated in
the BHC Act (12 U.S.C. 1842(c)). If the
proposal also involves the acquisition of
a nonbanking company, the review also
includes whether the acquisition of the
nonbanking company complies with the
standards in section 4 of the BHC Act
(12 U.S.C. 1843). Unless otherwise
noted, nonbanking activities will be
conducted throughout the United States.
Additional information on all bank
holding companies may be obtained
from the National Information Center
website at www.ffiec.gov/nic/.
Unless otherwise noted, comments
regarding each of these applications
must be received at the Reserve Bank
indicated or the offices of the Board of
Governors not later than May 27, 2005.
A. Federal Reserve Bank of St. Louis
(Glenda Wilson, Community Affairs
Officer) 411 Locust Street, St. Louis,
Missouri 63166-2034:
1. Trubank Securities Trust, St. Louis,
Missouri; to become a bank holding
company by acquiring 16 percent of the
voting shares of Truman Bancorp, Inc.,
St. Louis, Missouri, and thereby
indirectly acquire Truman Bank, St.
Louis, Missouri.
B. Federal Reserve Bank of Chicago
(Patrick M. Wilder, Assistant Vice
President) 230 South LaSalle Street,
Chicago, Illinois 60690-1414:
1. Evans Bancshares, Inc., Evansdale,
Iowa; to acquire 100 percent of the
voting shares of First Resource Bank,
Savage, Minnesota (in organization).
Board of Governors of the Federal Reserve
System, April 27, 2005.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. 05–8742 Filed 5–2–05; 8:45 am]
22865
determined by Order to be closely
related to banking and permissible for
bank holding companies. Unless
otherwise noted, these activities will be
conducted throughout the United States.
Each notice is available for inspection
at the Federal Reserve Bank indicated.
The notice also will be available for
inspection at the offices of the Board of
Governors. Interested persons may
express their views in writing on the
question whether the proposal complies
with the standards of section 4 of the
BHC Act. Additional information on all
bank holding companies may be
obtained from the National Information
Center website at www.ffiec.gov/nic/.
Unless otherwise noted, comments
regarding the applications must be
received at the Reserve Bank indicated
or the offices of the Board of Governors
not later than May 17, 2005.
A. Federal Reserve Bank of Atlanta
(Andre Anderson, Vice President) 1000
Peachtree Street, N.E., Atlanta, Georgia
30303:
1. BankEast Corporation, Knoxville,
Tennessee; to acquire Curtis Mortgage
Company, Inc., Knoxville, Tennessee,
and thereby engage in brokering
residential and investor real estate loans
in the secondary market, pursuant to
section 225.28(b)(1) of Regulation Y.
Board of Governors of the Federal Reserve
System, April 27, 2005.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. 05–8740 Filed 5–2–05; 8:45 am]
BILLING CODE 6210–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Formations of, Acquisitions by, and
Mergers of Bank Holding Companies
BILLING CODE 6210–01–S
Solicitation of Nomination for
Appointment to the Advisory
Committee on Blood Safety and
Availability
The companies listed in this notice
have applied to the Board for approval,
pursuant to the Bank Holding Company
Act of 1956 (12 U.S.C. 1841 et seq.)
(BHC Act), Regulation Y (12 CFR Part
225), and all other applicable statutes
and regulations to become a bank
holding company and/or to acquire the
assets or the ownership of, control of, or
the power to vote shares of a bank or
bank holding company and all of the
banks and nonbanking companies
owned by the bank holding company,
including the companies listed below.
The applications listed below, as well
as other related filings required by the
Board, are available for immediate
inspection at the Federal Reserve Bank
indicated. The application also will be
FEDERAL RESERVE SYSTEM
AGENCY:
FEDERAL RESERVE SYSTEM
VerDate jul<14>2003
16:54 May 02, 2005
Jkt 205001
Notice of Proposals to Engage in
Permissible Nonbanking Activities or
to Acquire Companies that are
Engaged in Permissible Nonbanking
Activities
The companies listed in this notice
have given notice under section 4 of the
Bank Holding Company Act (12 U.S.C.
1843) (BHC Act) and Regulation Y (12
CFR Part 225) to engage de novo, or to
acquire or control voting securities or
assets of a company, including the
companies listed below, that engages
either directly or through a subsidiary or
other company, in a nonbanking activity
that is listed in § 225.28 of Regulation Y
(12 CFR 225.28) or that the Board has
PO 00000
Frm 00025
Fmt 4703
Sfmt 4703
Department of Health and
Human Services, Office of the Secretary.
ACTION: Notice.
Authority: 42 U.S.C. 217a, Section 222 of
the Public Health Service Act, as amended.
The Advisory Committee on Blood Safety
and Availability is governed by the
provisions of Public Law 92–463, as
amended (5 U.S.C. Appendix 2) which sets
forth standards for the formation and use of
advisory committees.
SUMMARY: The Department of Health and
Human Services (DHHS), Office of
Public Health and Science, is seeking
nominations of qualified candidates to
be considered for appointment as a
member of the Advisory Committee on
Blood Safety and Availability (ACBSA).
E:\FR\FM\03MYN1.SGM
03MYN1
22866
Federal Register / Vol. 70, No. 84 / Tuesday, May 3, 2005 / Notices
The ACBSA provides advice to the
Secretary and the Assistant Secretary for
Health on blood safety policy issues
which encompass broad public health
and societal implications that cannot be
resolved through analysis of scientific
data alone.
DATES: All nominations must be
received at the address below no later
than 4 p.m. e.s.t. May 30, 2005.
ADDRESSES: All nominations should be
mailed or delivered to Jerry Holmberg,
Ph.D., Executive Secretary, Advisory
Committee on Blood Safety and
Availability, Office of Public Health and
Science, Department of Health and
Human Services, 1101 Wootton
Parkway, Suite 250, Rockville, MD
20852.
FOR FURTHER INFORMATION CONTACT: Jerry
Holmberg, Ph.D., Executive Secretary,
Advisory Committee on Blood Safety
and Availability, Office of Public Health
and Science, Department of Health and
Human Services, 1101 Wootton
Parkway, Suite 250, Rockville, MD
20852. Telephone (301) 443–2331.
A copy of the Committee charter and
a list of the current membership can be
obtained by contacting Dr. Holmberg.
SUPPLEMENTARY INFORMATION: The
ACBSA provides advice to the Secretary
and the Assistant Secretary for Health
on a broad range of policy issues
regarding the collection, preparation,
and distribution of blood and blood
products, and regulations related to the
transmission of communicable diseases.
The range of policy issues that the
ACBSA provides advice on includes: (1)
Definition of public health parameters
around safety and availability of blood
supply; (2) broad public health, ethical
and legal issues related to blood safety,
and (3) the implications for blood safety
availability of various economic factors
affecting product cost and supply.
The ACBSA consists of 18 voting
members. The Committee is composed
of 12 members, including the Chair, and
6 representative members. The public
members are selected from State and
local organizations, advocacy groups,
provider organizations, academic
researchers, ethicists, private
physicians, scientists, consumer
advocates, legal organizations, and from
among communities of persons who are
frequent recipients of blood or blood
products. The representative members
are designated to serve as official
representatives of the blood and blood
products industry or professional
organizations. The representative
members shall represent the American
Association of Blood Banks, one or two
major distributors of blood on a rotating
basis, a trade organization or
VerDate jul<14>2003
15:43 May 02, 2005
Jkt 205001
manufacturer of blood test kits or
equipment, a company that produces
leukoreduction processes, a major
hospital organization that purchases
blood and blood products, and a plasma
protein therapeutic association.
Nominations
The Office of Public Health and
Science is seeking nominations to fill
several positions on the ACBSA that are
scheduled to be vacated on September
30, 2005. The positions to be vacated are
from both classifications—the public
members and the representative
members.
To qualify for consideration as a
public member, individuals should
possess authoritative knowledge in
blood banking, transfusion medicine,
plasma therapies, bioethics, and/or
related disciplines. Public members will
be selected from the categories
previously described.
The terms of appointment for the
representative member of the following
also are scheduled to end: a trade
organization or manufacturer of blood
test kits or equipment, a company that
produces leukoreduction processes, a
major hospital organization that
purchases blood and blood products,
and a plasma protein therapeutic
association. This notice is intended to
solicit nominations from the blood and
blood products industry and
professional organizations of qualified
candidates to serve as official
representatives for the specified interest
groups or industry.
Individuals are invited to serve as
members of the Committee for
overlapping three year terms. Public
members of the Committee receive a
stipend for attending Committee
meetings, as well as for conducting
other business in the interest of the
Committee.
Pursuant to advance written
agreement, members who are appointed
as representatives of a particular interest
group or industry serve without
compensation. All members are
authorized to receive prescribed per
diem allowances and reimbursement for
expenses incurred when performing
travel to conduct Committee-related
business matters.
Nominations should be typewritten.
The following information should be
included in the package of material
submitted for each individual being
nominated for consideration: (1) A letter
of nomination that clearly states the
name and affiliation of the nominee, the
basis for the nomination (i.e., specific
attributes which qualify the nominee for
service in this capacity), and a statement
that the nominee is willing to serve as
PO 00000
Frm 00026
Fmt 4703
Sfmt 4703
a member of the Committee; (2) the
nominator’s name, address, and daytime
telephone number, and the home and/
or work address, telephone number and
e-mail address of the person being
nominated; and (3) a current copy of the
nominee’s curriculum vitae. The names
of Federal employees should not be
nominated for consideration of
appointment for this Committee.
The Department makes every effort to
ensure that membership of DHHS
Federal advisory committees is fairly
balanced in terms of points of view
represented and the committee’s
function. Every effort is made to ensure
that a broad representation of
geographic areas, females, ethnic and
minority groups, and the disabled are
given consideration for membership on
DHHS Federal advisory committees.
Appointment to this Committee shall be
made without discrimination on the
basis of age, race, ethnicity, gender,
sexual orientation, disability, and
cultural, religious, or socioeconomic
status.
Nominations must state that the
nominee is willing to serve as a member
of ACBSA and appears to have no
conflict of interest that would preclude
membership. An ethics review is
conducted for each selected candidate.
Therefore, individuals selected for
nomination will be required to provide
detailed information concerning such
matters as financial holdings,
consultancies, and research grants or
contracts to permit evaluation of
possible sources of conflict of interest.
Dated: April 25, 2005.
Jerry A. Holmberg,
Executive Secretary, Advisory Committee on
Blood Safety and Availability.
[FR Doc. 05–8773 Filed 5–2–05; 8:45 am]
BILLING CODE 4150–41–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Notice of Meeting: Secretary’s
Advisory Committee on Genetics,
Health, and Society
Pursuant to Pub. L. 92–463, notice is
hereby given of the seventh meeting of
the Secretary’s Advisory Committee on
Genetics, Health, and Society
(SACGHS), U.S. Public Health Service.
The meeting will be held from 8:30 a.m.
to 5:30 p.m. on June 15, 2005, and 8:30
a.m. to 5:30 p.m. on June 16, 2005, at
the Bethesda North Marriott Hotel, 5701
Marinelli Road, North Bethesda,
Maryland. The meeting will be open to
the public with attendance limited to
E:\FR\FM\03MYN1.SGM
03MYN1
]]>Agencies
[Federal Register Volume 70, Number 84 (Tuesday, May 3, 2005)]
[Notices]
[Pages 22865-22866]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-8773]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Solicitation of Nomination for Appointment to the Advisory
Committee on Blood Safety and Availability
AGENCY: Department of Health and Human Services, Office of the
Secretary.
ACTION: Notice.
-----------------------------------------------------------------------
Authority: 42 U.S.C. 217a, Section 222 of the Public Health
Service Act, as amended. The Advisory Committee on Blood Safety and
Availability is governed by the provisions of Public Law 92-463, as
amended (5 U.S.C. Appendix 2) which sets forth standards for the
formation and use of advisory committees.
SUMMARY: The Department of Health and Human Services (DHHS), Office of
Public Health and Science, is seeking nominations of qualified
candidates to be considered for appointment as a member of the Advisory
Committee on Blood Safety and Availability (ACBSA).
[[Page 22866]]
The ACBSA provides advice to the Secretary and the Assistant
Secretary for Health on blood safety policy issues which encompass
broad public health and societal implications that cannot be resolved
through analysis of scientific data alone.
DATES: All nominations must be received at the address below no later
than 4 p.m. e.s.t. May 30, 2005.
ADDRESSES: All nominations should be mailed or delivered to Jerry
Holmberg, Ph.D., Executive Secretary, Advisory Committee on Blood
Safety and Availability, Office of Public Health and Science,
Department of Health and Human Services, 1101 Wootton Parkway, Suite
250, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Jerry Holmberg, Ph.D., Executive
Secretary, Advisory Committee on Blood Safety and Availability, Office
of Public Health and Science, Department of Health and Human Services,
1101 Wootton Parkway, Suite 250, Rockville, MD 20852. Telephone (301)
443-2331.
A copy of the Committee charter and a list of the current
membership can be obtained by contacting Dr. Holmberg.
SUPPLEMENTARY INFORMATION: The ACBSA provides advice to the Secretary
and the Assistant Secretary for Health on a broad range of policy
issues regarding the collection, preparation, and distribution of blood
and blood products, and regulations related to the transmission of
communicable diseases. The range of policy issues that the ACBSA
provides advice on includes: (1) Definition of public health parameters
around safety and availability of blood supply; (2) broad public
health, ethical and legal issues related to blood safety, and (3) the
implications for blood safety availability of various economic factors
affecting product cost and supply.
The ACBSA consists of 18 voting members. The Committee is composed
of 12 members, including the Chair, and 6 representative members. The
public members are selected from State and local organizations,
advocacy groups, provider organizations, academic researchers,
ethicists, private physicians, scientists, consumer advocates, legal
organizations, and from among communities of persons who are frequent
recipients of blood or blood products. The representative members are
designated to serve as official representatives of the blood and blood
products industry or professional organizations. The representative
members shall represent the American Association of Blood Banks, one or
two major distributors of blood on a rotating basis, a trade
organization or manufacturer of blood test kits or equipment, a company
that produces leukoreduction processes, a major hospital organization
that purchases blood and blood products, and a plasma protein
therapeutic association.
Nominations
The Office of Public Health and Science is seeking nominations to
fill several positions on the ACBSA that are scheduled to be vacated on
September 30, 2005. The positions to be vacated are from both
classifications--the public members and the representative members.
To qualify for consideration as a public member, individuals should
possess authoritative knowledge in blood banking, transfusion medicine,
plasma therapies, bioethics, and/or related disciplines. Public members
will be selected from the categories previously described.
The terms of appointment for the representative member of the
following also are scheduled to end: a trade organization or
manufacturer of blood test kits or equipment, a company that produces
leukoreduction processes, a major hospital organization that purchases
blood and blood products, and a plasma protein therapeutic association.
This notice is intended to solicit nominations from the blood and blood
products industry and professional organizations of qualified
candidates to serve as official representatives for the specified
interest groups or industry.
Individuals are invited to serve as members of the Committee for
overlapping three year terms. Public members of the Committee receive a
stipend for attending Committee meetings, as well as for conducting
other business in the interest of the Committee.
Pursuant to advance written agreement, members who are appointed as
representatives of a particular interest group or industry serve
without compensation. All members are authorized to receive prescribed
per diem allowances and reimbursement for expenses incurred when
performing travel to conduct Committee-related business matters.
Nominations should be typewritten. The following information should
be included in the package of material submitted for each individual
being nominated for consideration: (1) A letter of nomination that
clearly states the name and affiliation of the nominee, the basis for
the nomination (i.e., specific attributes which qualify the nominee for
service in this capacity), and a statement that the nominee is willing
to serve as a member of the Committee; (2) the nominator's name,
address, and daytime telephone number, and the home and/or work
address, telephone number and e-mail address of the person being
nominated; and (3) a current copy of the nominee's curriculum vitae.
The names of Federal employees should not be nominated for
consideration of appointment for this Committee.
The Department makes every effort to ensure that membership of DHHS
Federal advisory committees is fairly balanced in terms of points of
view represented and the committee's function. Every effort is made to
ensure that a broad representation of geographic areas, females, ethnic
and minority groups, and the disabled are given consideration for
membership on DHHS Federal advisory committees. Appointment to this
Committee shall be made without discrimination on the basis of age,
race, ethnicity, gender, sexual orientation, disability, and cultural,
religious, or socioeconomic status.
Nominations must state that the nominee is willing to serve as a
member of ACBSA and appears to have no conflict of interest that would
preclude membership. An ethics review is conducted for each selected
candidate. Therefore, individuals selected for nomination will be
required to provide detailed information concerning such matters as
financial holdings, consultancies, and research grants or contracts to
permit evaluation of possible sources of conflict of interest.
Dated: April 25, 2005.
Jerry A. Holmberg,
Executive Secretary, Advisory Committee on Blood Safety and
Availability.
[FR Doc. 05-8773 Filed 5-2-05; 8:45 am]
BILLING CODE 4150-41-P
